Is Regeneron a Multimillionaire-Maker Stock?
(NASDAQ: REGN) has encountered several headwinds over the past two years, including the loss of patent exclusivity for one of its growth drivers, Eylea, a medicine for wet age-related macular degeneration. Even as its long-term returns remain solid, the stock has not performed particularly well over the last 24 months. There are several reasons why Regeneron could bounce back -- in fact, it has already begun to do so, with its shares up 35% over the past six months.
But does the biotech have what it takes to crush the market over the long run and turn average investors into multimillionaires?
Image source: Getty Images.
Source Fool.com
Regeneron Pharmaceuticals Inc. Stock
€594.30
0.150%
The stock is an absolute favorite of our community with 43 Buy predictions and no Sell predictions.
With a target price of 714 € there is a positive potential of 20.14% for Regeneron Pharmaceuticals Inc. compared to the current price of 594.3 €.
